SENS Research Foundation

SENS Research Foundation is a California nonprofit established in 2009 to fund research on Strategies for Engineered Negligible Senescence, a framework that treats aging as the accumulation of seven classes of cellular and molecular damage, each of which is to be repaired directly rather than prevented. Spun out of the Methuselah Foundation by Aubrey de Grey and colleagues, it was for a decade the main institutional home of the damage-repair approach to aging. It removed de Grey in 2021 after allegations of misconduct, and rebranded as the Lifespan Research Institute in 2024.

§Overview

The SENS framework's distinguishing claim is engineering rather than biological. Its proponents argue that understanding the metabolic processes that generate damage is not necessary in order to remove the damage, in the same way that a mechanic need not understand combustion chemistry to replace a corroded part. This is a deliberate contrast with the mainstream Geroscience hypothesis, which seeks to slow damage accumulation by modulating pathways such as mTOR and nutrient sensing with drugs like Rapamycin, and with the descriptive Hallmarks of aging framework, which SENS advocates regard as a taxonomy that stops short of telling anyone what to build.

The framework enumerates seven damage categories, and asserts that the list is complete in the sense that no new class of damage has been discovered since the 1980s:

• cell loss and tissue atrophy
• death-resistant cells, principally senescent cells
• nuclear mutations and epimutations, which matter chiefly through cancer
• mitochondrial DNA mutations
• intracellular aggregates that lysosomes cannot degrade
• extracellular aggregates such as amyloid
• extracellular protein crosslinks, principally glucosepane in collagen

Repair or slow down

The damage-repair position holds that intervention should target the accumulated products of aging, which are enumerable, rather than the metabolism that produces them, which is not fully understood. Most biogerontologists regard the seven-category list as an assertion rather than a finding, and note that the boundary between damage and normal biological variation is not sharp. The disagreement is about research strategy, not about whether damage accumulates.

§History

De Grey developed the framework in the early 2000s, initially at Cambridge, and set out its full form in 2007 in Ending Aging, written with Michael Rae.¹ The Methuselah Foundation, which de Grey had co-founded with David Gobel in the early 2000s, funded early SENS work; in 2009 SENS Foundation was incorporated separately with de Grey, Michael Kope, Jeff Hall, Sarah Marr and Kevin Perrott among its founders.

The organization ran an intramural laboratory in Mountain View, funded extramural projects at universities, and operated an education programme that placed undergraduates in aging laboratories. Its early funding came heavily from individual donors in the technology sector, including a substantial early gift from Peter Thiel and, later, cryptocurrency donations from Vitalik Buterin.

1. 2000s
   The framework
   Aubrey de Grey formulates the seven-category damage-repair model and argues it in the biogerontology literature and in Ending Aging.
2. 2005
   The MIT challenge
   MIT Technology Review offers a prize for a refutation of SENS; judges conclude that the framework has not been disproven but is not scientifically demonstrated either.
3. 2009
   SENS Foundation founded
   The programme is spun out of the Methuselah Foundation as an independent nonprofit with its own laboratory in Mountain View.
4. 2010s
   Spin-outs
   Funded projects yield companies including Cyclarity Therapeutics, working on cyclodextrins for arterial cholesterol, and Revel Pharmaceuticals, working on crosslink-breaking enzymes.
5. 2021
   Governance crisis
   Allegations of misconduct lead to de Grey being placed on leave and then removed; he denies wrongdoing and later founds the LEV Foundation.
6. 2024
   Renamed
   The organization becomes the Lifespan Research Institute, retaining the damage-repair research agenda under new leadership.

§Research programme

The foundation's approach was to fund the categories that no one else was working on. Cell loss is addressed by mainstream regenerative medicine and stem cell research; cancer attracts enormous investment; senescent cells acquired a large commercial following after 2015 with the rise of Senolytics. The organization concentrated its own money on the neglected remainder.

Two lines produced spin-out companies. Work on lysosomal aggregates in atherosclerosis — 7-ketocholesterol, which macrophages cannot degrade and which contributes to foam-cell formation — led to Cyclarity Therapeutics, founded by Matthew O'Connor, which developed an engineered cyclodextrin intended to extract the molecule from plaque and began first-in-human testing in Australia in the mid-2020s. Work on glucosepane, the dominant crosslink in aged human collagen, led to Revel Pharmaceuticals, founded with the Yale chemist David Spiegel, which pursued enzymes capable of cleaving it.

A third line, mitochondrial gene therapy by allotopic expression — inserting backup copies of the thirteen mitochondrially encoded genes into the nucleus so that a cell with damaged mitochondrial DNA can still make the proteins — was pursued in the foundation's own laboratory and produced published results for a subset of the genes. It has not reached human testing, and the approach is distinct from the germline replacement techniques used to prevent inherited mitochondrial disease.

§The 2005 challenge

In 2005 MIT Technology Review offered a prize to any molecular biologist who could demonstrate that SENS was "so wrong that it is unworthy of learned debate". Submissions were judged by a panel including Rodney Brooks, Anita Goel, Nathan Myhrvold, Vikram Sheel Kumar and J. Craig Venter. No prize was awarded. The judges' conclusion, which both sides have quoted selectively ever since, was that the critics had not proven SENS false but that de Grey had not proven it plausible either, and that it belonged in the category of ideas that are unsupported rather than refuted.² Two decades later that verdict has aged well: several SENS categories have become mainstream research areas, and none has produced a demonstrated human rejuvenation therapy.

§Funding

The organization has always been philanthropically funded, with annual budgets in the single-digit millions of dollars — small relative to Calico Life Sciences or Altos Labs by three orders of magnitude, and small relative to national aging-research budgets. Its donor base was concentrated, which made it vulnerable to the loss of individual supporters and shaped the governance problems that followed.

Cryptocurrency donations were significant during the 2017 and 2021 market peaks and volatile in the way that implies. Nominal values reported at the time of donation frequently exceeded what was realized.

§The 2021 crisis and rebranding

In August 2021 two women made public allegations concerning de Grey's conduct. The foundation placed him on administrative leave and commissioned an independent investigation, then terminated his employment. The investigation's reported conclusion was that it had not substantiated a finding of sexual harassment but that de Grey had improperly interfered with the investigation itself. De Grey denied wrongdoing throughout and subsequently reached a settlement with the organization; he founded the Longevity Escape Velocity Foundation in 2022, named for the Longevity escape velocity threshold he had popularized, to run large mouse studies combining several interventions at once.

The episode cost the organization donors, staff and its most recognizable public figure at once. Under new leadership it narrowed its programme, and in 2024 renamed itself the Lifespan Research Institute, a change that separated the organization's identity from both the SENS acronym and its founder.

§Reception and legacy

Mainstream biogerontology has never accepted the SENS framework as a theory, and a 2005 rebuttal in EMBO Reports signed by a group of prominent aging researchers argued that it presents speculative proposals as an engineering roadmap and that none of the seven interventions had a demonstrated route to the clinic.³ That criticism was substantially correct at the time and remains largely correct.

The foundation's actual influence runs through people and topics rather than through the framework. It funded senescent-cell work before senolytics were fashionable, kept crosslink chemistry and lysosomal aggregate research alive when no one else would pay for them, and trained a cohort of researchers now distributed across the field and the Buck Institute for Research on Aging and comparable centres. It also normalized the idea that aging is a legitimate target for intervention rather than an inevitability, which made the funding environment that produced Altos, Retro Biosciences and XPRIZE Healthspan easier to create.

Whether the seven-category framework is the right decomposition remains unsettled. It is at least falsifiable in principle: if a repair therapy for one category produced a measurable rejuvenation in a mammal without touching the others, the framework's modular premise would gain support it currently lacks.

§See also

• Aubrey de Grey
• Methuselah Foundation
• Longevity escape velocity
• Senolytics
• Hallmarks of aging
• Geroscience hypothesis
• Buck Institute for Research on Aging
• Negligible senescence

§References